Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$11.05
-1.15 (-9.43%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-76.8M · quality 73.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-44.0%
↓Gross Margin
14.3%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+33.3%
FCF CAGR
—
FCF margin
-194.9%
FCF / Net income
0.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $69.0M · net income $-184.4M · FCF $-134.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $69.0M | $69.0M | $32.3M | $46.1M | $29.1M |
| Net Income | $-184.4M | $-184.4M | $-99.3M | $-70.8M | $-103.2M |
| EBITDA | $-174.2M | $-174.2M | $-90.0M | $-63.2M | $-94.6M |
| EPS | — | — | -1.01 | -0.76 | -1.17 |
| Gross Margin | 14.3% | 14.3% | 64.3% | 37.9% | -1.3% |
| Operating Margin | -249.0% | -249.0% | -278.3% | -140.7% | -322.1% |
| Net Margin | -267.3% | -267.3% | -307.4% | -153.7% | -354.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.03 | 0.05 | 0.09 |
| Current Ratio | 3.52 | 3.52 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-134.5M | $-134.5M | $-76.8M | $-49.0M | $-100.2M |
| Returns | |||||
| ROE | -44.0% | -44.0% | -16.5% | -14.9% | -23.9% |
| Valuation | |||||
| P/B | 2.85 | 2.85 | 2.80 | 3.33 | 2.38 |
| Growth & Yield | |||||
| Revenue Growth | 113.6% | 113.6% | -29.9% | 58.1% | — |
| EPS Growth | — | — | -32.5% | 34.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.01 → n/d
Residual
-33.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.